SPP1 and myeloid sarcoma: Cerebrospinal fluid osteopontin levels were reduced in patients during natalizumab treatment but it is unknown if these levels are predictive of natalizumab response.40 More studies assessing of the role of this biomarker during natalizumab and other MS treatments are still required.